collection
MENU ▼
Read by QxMD icon Read
search

Lymphoma

shared collection
50 papers 25 to 100 followers My list of recent lymphoma publications
https://www.readbyqxmd.com/read/28251914/rituximab-exposure-is-influenced-by-baseline-metabolic-tumor-volume-and-predicts-outcome-of-dlbcl-patients-a-lysa-study
#1
Mira Tout, Olivier Casasnovas, Michel Meignan, Thierry Lamy, Franck Morschhauser, Gilles Salles, Emmanuel Gyan, Corinne Haioun, Mélanie Mercier, Pierre Feugier, Sami Boussetta, Gilles Paintaud, David Ternant, Guillaume Cartron
High variability in patient outcome after rituximab-based treatment is partly explained by rituximab concentrations, and pharmacokinetic variability could be influenced by tumor burden. We aimed at quantifying the influence of baseline total metabolic tumor volume (TMTV0) on rituximab pharmacokinetics and of TMTV0 and rituximab exposure on outcome in patients with diffuse large B-cell lymphoma (DLBCL). TMTV0 was measured by (18)F-FDG-PET/CT in 108 previously untreated DLBCL patients who received four 375 mg/m(2) rituximab infusions every 2 weeks in combination with chemotherapy in two prospective trials...
March 1, 2017: Blood
https://www.readbyqxmd.com/read/26712084/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced-non-small-cell-lung-cancer-keynote-010-a-randomised-controlled-trial
#2
RANDOMIZED CONTROLLED TRIAL
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled-Filhart, Edward B Garon
BACKGROUND: Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. METHODS: We did this randomised, open-label, phase 2/3 study at 202 academic medical centres in 24 countries. Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m(2) every 3 weeks...
April 9, 2016: Lancet
https://www.readbyqxmd.com/read/28011673/distinct-patterns-of-b-cell-receptor-signaling-in-non-hodgkin-lymphomas-identified-by-single-cell-profiling
#3
June H Myklebust, Joshua Brody, Holbrook E Kohrt, Arne Kolstad, Debra K Czerwinski, Sébastien Wälchli, Michael R Green, Gunhild Trøen, Knut Liestøl, Klaus Beiske, Roch Houot, Jan Delabie, Ash A Alizadeh, Jonathan M Irish, Ronald Levy
Kinases downstream of B-cell antigen receptor (BCR) represent attractive targets for therapy in non-Hodgkin lymphoma (NHL). As clinical responses vary, improved knowledge regarding activation and regulation of BCR signaling in individual patients is needed. Here, using phosphospecific flow cytometry to obtain malignant B-cell signaling profiles from 95 patients representing 4 types of NHL revealed a striking contrast between chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) tumors. Lymphoma cells from diffuse large B-cell lymphoma patients had high basal phosphorylation levels of most measured signaling nodes, whereas follicular lymphoma cells represented the opposite pattern with no or very low basal levels...
February 9, 2017: Blood
https://www.readbyqxmd.com/read/28099514/pet-ct-scanner-and-bone-marrow-biopsy-in-detection-of-bone-marrow-involvement-in-diffuse-large-b-cell-lymphoma
#4
Fadi El Karak, Ibrahim R Bou-Orm, Marwan Ghosn, Joseph Kattan, Fadi Farhat, Toni Ibrahim, Mario Jreige, Jean El Cheikh, Mohamad Haidar
Evaluation of bone marrow involvement (BMI) is paramount in diffuse large B-cell lymphoma (DLBCL) for prognostic and therapeutic reasons. PET/CT scanner (PET) is now a routine examination for the staging of DLBCL with prognostic and therapeutic implications. This study evaluates the role of PET for detecting marrow involvement compared to bone marrow biopsy (BMB). This monocentric study included 54 patients diagnosed with DLBCL between 2009 and 2013 and who had FDG PET/CT in a pre-treatment setting. A correlation analysis of the detection of BMI by PET and BMB was performed...
2017: PloS One
https://www.readbyqxmd.com/read/28096090/how-i-manage-ibrutinib-refractory-chronic-lymphocytic-leukemia
#5
REVIEW
Jennifer A Woyach
The introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib has dramatically changed the management of chronic lymphocytic leukemia (CLL). Although responses have been durable in the majority of patients, relapses do occur, especially in the high-risk patient population. Most relapses occur as the result of acquired mutations in BTK and PLCG2, which may facilitate success with alternative targeted therapies. As outcomes after ibrutinib relapse have been reported to be poor, specific strategies are needed for this patient population...
March 9, 2017: Blood
https://www.readbyqxmd.com/read/28094456/waldenstr%C3%A3-m-macroglobulinemia-2017-update-on-diagnosis-risk-stratification-and-management
#6
Morie A Gertz
Disease Overview: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. DIAGNOSIS: Presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in more than 90% of patients. Risk Stratification: Age, hemoglobin level, platelet count, β2 microglobulin, and monoclonal IgM concentrations are characteristics required for prognosis...
February 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28130034/nice-guidance-on-ibrutinib-for-previously-treated-chronic-lymphocytic-leukaemia-and-untreated-chronic-lymphocytic-leukaemia-in-the-presence-of-17p-deletion-or-tp53-mutation
#7
Boglarka Mikudina, Melinda Goodall, Amanda I Adler
No abstract text is available yet for this article.
January 24, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27904766/the-role-of-pim1-in-the-ibrutinib-resistant-abc-subtype-of-diffuse-large-b-cell-lymphoma
#8
Hsu-Ping Kuo, Scott A Ezell, Sidney Hsieh, Karl J Schweighofer, Leo Wk Cheung, Shiquan Wu, Mutiah Apatira, Mint Sirisawad, Karl Eckert, Yu Liang, Jeff Hsu, Chun-Te Chen, Darrin Beaupre, Betty Y Chang
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous lymphoma and the most common subtype of non-Hodgkin lymphoma, accounting for roughly 30% of newly diagnosed cases in the United States. DLBCL can be separated into the activated B cell-like (ABC) and germinal center B cell-like (GCB) subtypes, with distinct gene expression profiles, oncogenic aberrations, and clinical outcomes. ABC-DLBCL is characterized by chronically active B-cell receptor (BCR) signaling that can be modulated by Bruton's tyrosine kinase (BTK) activity...
2016: American Journal of Cancer Research
https://www.readbyqxmd.com/read/27650702/cutaneous-b-cell-lymphomas-2016-update-on-diagnosis-risk-stratification-and-management
#9
Ryan A Wilcox
DISEASE OVERVIEW: Approximately one-fourth of cutaneous lymphomas are B-cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT). DIAGNOSIS: Diagnosis and disease classification is based on histologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B-cell lymphomas from systemic B-cell lymphomas with secondary skin involvement...
October 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/27708232/a-strong-host-response-and-lack-of-myc-expression-are-characteristic-for-diffuse-large-b-cell-lymphoma-transformed-from-nodular-lymphocyte-predominant-hodgkin-lymphoma
#10
Bianca Schuhmacher, Benjamin Rengstl, Claudia Döring, Julia Bein, Sebastian Newrzela, Uta Brunnberg, Hans Michael Kvasnicka, Martine Vornanen, Ralf Küppers, Martin-Leo Hansmann, Sylvia Hartmann
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent lymphoma, but can transform into diffuse large B cell lymphoma (DLBCL), showing a more aggressive clinical behavior. Little is known about these cases on the molecular level. Therefore, the aim of the present study was to characterize DLBCL transformed from NLPHL (LP-DLBCL) by gene expression profiling (GEP). GEP revealed an inflammatory signature pinpointing to a specific host response. In a coculture model resembling this host response, DEV tumor cells showed an impaired growth behavior...
September 30, 2016: Oncotarget
https://www.readbyqxmd.com/read/27805626/pd-1-pd-l1-immune-checkpoint-blockade-in-b-cell-lymphomas
#11
REVIEW
Aaron Goodman, Sandip P Patel, Razelle Kurzrock
Cancer cells can escape T-cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immune checkpoint. Indeed, therapeutic antibodies that block the PD-1-PD-L1 axis induce durable clinical responses against a growing list of solid tumours. B-cell lymphomas also leverage this checkpoint to escape immune recognition, although the outcomes of PD-1-PD-L1 blockade, and the correlations between PD-L1 expression and treatment responses, are less-well elucidated in these diseases than in solid cancers...
April 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27701070/esmo-consensus-conference-on-malignant-lymphoma-general-perspectives-and-recommendations-for-prognostic-tools-in-mature-b-cell-lymphomas-and-chronic-lymphocytic-leukaemia
#12
M Ladetto, C Buske, M Hutchings, M Dreyling, G Gaidano, S Le Gouill, S Luminari, C Pott, A Zamò, E Zucca
The European Society for Medical Oncology (ESMO) consensus conference on mature B-cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (i) the elderly patient, (ii) prognostic factors suitable for clinical use and (iii) the 'ultra-high-risk' group...
December 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27351173/management-strategies-and-outcomes-for-very-elderly-patients-with-diffuse-large-b-cell-lymphoma
#13
Dai Chihara, Jason R Westin, Yasuhiro Oki, Mohamed A Ahmed, Bryan Do, Luis E Fayad, Fredrick B Hagemeister, Jorge E Romaguera, Michelle A Fanale, Hun J Lee, Francesco Turturro, Felipe Samaniego, Sattva S Neelapu, M Alma Rodriguez, Nathan H Fowler, Michael Wang, Richard E Davis, Loretta J Nastoupil
BACKGROUND: The number of elderly patients with diffuse large B-cell lymphoma (DLBCL) in our aging society continues to rise, although the optimal management of very elderly patients with DLBCL is unknown. METHODS: This study evaluated 207 patients who were 80 years old or older at the diagnosis of DLBCL from 2002 to 2014 at The University of Texas MD Anderson Cancer Center. Analyzed features included clinical characteristics, treatment outcomes, and tolerability of therapy...
October 15, 2016: Cancer
https://www.readbyqxmd.com/read/27737845/cll-an-acquired-immunodeficiency-disease
#14
Clive S Zent
No abstract text is available yet for this article.
October 13, 2016: Blood
https://www.readbyqxmd.com/read/27664263/newly-diagnosed-and-relapsed-follicular-lymphoma-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#15
M Dreyling, M Ghielmini, S Rule, G Salles, U Vitolo, M Ladetto
No abstract text is available yet for this article.
September 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27799164/how-i-treat-cryoglobulinemia
#16
REVIEW
Eli Muchtar, Hila Magen, Morie A Gertz
Cryoglobulinemia is a distinct entity characterized by the presence of cryoglobulins in the serum. Cryoglobulins differ in their composition, which has an impact on the clinical presentation and the underlying disease that triggers cryoglobulin formation. Cryoglobulinemia is categorized into two main subgroups: type I, which is seen exclusively in clonal hematologic diseases, and type II/III, which is called mixed cryoglobulinemia and is seen in hepatitis C virus infection and systemic diseases such as B-cell lineage hematologic malignancies and connective tissue disorders...
January 19, 2017: Blood
https://www.readbyqxmd.com/read/27187305/surveillance-imaging-in-patients-in-remission-from-hodgkin-and-diffuse-large-b-cell-lymphoma
#17
Chadi Nabhan, Sonali M Smith, Adam S Cifu
No abstract text is available yet for this article.
May 17, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27049457/safety-tolerability-and-preliminary-activity-of-cudc-907-a-first-in-class-oral-dual-inhibitor-of-hdac-and-pi3k-in-patients-with-relapsed-or-refractory-lymphoma-or-multiple-myeloma-an-open-label-dose-escalation-phase-1-trial
#18
Anas Younes, Jesus G Berdeja, Manish R Patel, Ian Flinn, John F Gerecitano, Sattva S Neelapu, Kevin R Kelly, Amanda R Copeland, Amy Akins, Myles S Clancy, Lucy Gong, Jing Wang, Anna Ma, Jaye L Viner, Yasuhiro Oki
BACKGROUND: Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited. CUDC-907 is an oral, first-in-class, small molecule that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematological malignancies. We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma...
May 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27643872/outcomes-of-diffuse-large-b-cell-lymphoma-patients-relapsing-after-autologous-stem-cell-transplantation-an-analysis-of-patients-included-in-the-coral-study
#19
E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, R Bouadballah, J Radford, M Bargetzi, V Ribrag, U Dührsen, D Ma, J Briere, C Thieblemont, E Bachy, C H Moskowitz, B Glass, C Gisselbrecht
In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and >2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32...
February 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27151994/engage-501-phase-ii-study-of-entinostat-sndx-275-in-relapsed-and-refractory-hodgkin-lymphoma
#20
Connie Lee Batlevi, Yvette Kasamon, R Gregory Bociek, Peter Lee, Lia Gore, Amanda Copeland, Rachel Sorensen, Peter Ordentlich, Scott Cruickshank, Lori Kunkel, Daniela Buglio, Francisco Hernandez-Ilizaliturri, Anas Younes
Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint antibodies. However, most patients do not achieve a complete response, therefore development of novel therapies is warranted to improve patient outcomes. In this phase II study, patients with relapsed or refractory Hodgkin lymphoma were treated with entinostat, an isoform selective histone deacetylase inhibitor. Forty-nine patients were enrolled: 33 patients on Schedule A (10 or 15 mg oral entinostat once every other week); 16 patients on Schedule B (15 mg oral entinostat once weekly in 3 of 4 weeks)...
August 2016: Haematologica
label_collection
label_collection
6645
1
2
2016-06-03 03:34:55
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"